CT­LA-4 bound for the clin­ic, Bris­tol-My­ers hands Cy­tomX $200M to kick off an ex­pand­ed dis­cov­ery pact

Over the last three years, Bris­tol-My­ers Squibb has been steer­ing four pre­clin­i­cal dis­cov­ery pro­grams it part­nered on with South San Fran­cis­co-based Cy­tomX, mov­ing the lead CT­LA-4 an­ti­body to a near-term IND fil­ing with an eye on first-in-hu­man tri­als.

And now Bris­tol-My­ers is sign­ing up for eight more projects — six in on­col­o­gy and two more out­side of can­cer, as Cy­tomX push­es ahead in the clin­ic with a PD-L1 check­point the CEO be­lieves can blitz its way through a pack of ri­vals and in­to the spot­light.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.